ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2025
Molecular subtypes and prognostic signature rooted in disulfidptosis highlight tumor microenvironment in lung adenocarcinoma.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- A Mitochondrial-Related Gene Signature for Diagnosis and Immune Microenvironment Modulation in Lung Cancer and Venous Thromboembolism.World journal of oncology · 2026Article
- Integrative multi-omics analysis identifies LIPA as a prognostic hub and ferroptosis regulator in lung adenocarcinoma.Molecular and cellular biochemistry · 2026Article
- Disulfidptosis: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Bisphenol A promotes esophageal carcinogenesis by activating the MMP1-PCOLCE regulatory axis and remodeling the tumor immune microenvironment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Disulfidptosis: Mechanisms, evidence boundaries, and translational opportunities.Redox biology · 2026Review
- Integrating network toxicology, machine learning, and single-cell sequencing systems to analyze autophagy core genes in lung adenocarcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- FZD5 drives macrophage-mediated immunomodulation and predicts prognosis in glioma: evidence from single-cell sequencing.BMC cancer · 2026Article
- ITGAX is associated with poor prognosis and an immune-inflammatory microenvironment in clear cell renal cell carcinoma.BMC cancer · 2026Article
- Alisertib exerts AURKA-independent antitumor activity in colon cancer by modulating immune-related pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Metabolic pathway signatures define prognostic subtypes of lung adenocarcinoma.Discover oncology · 2026Article
- Integrated pan-cancer profiling highlights OSR2 as a prognostic indicator and immune-associated biomarker.Discover oncology · 2026Article
- Basement membrane related genes in lung adenocarcinoma prognostic risk model based on single cell and bulk RNA sequencing and tumor microenvironment modulation.Discover oncology · 2026Article
- Construction of a diagnostic model for nasopharyngeal carcinoma using a consensus machine learning approach and study of immune infiltration characteristics.Discover oncology · 2026Article
- Multi-omics and machine learning integration of diverse cell death pathways optimize risk stratification and inform drug therapy in Wilms tumor.Discover oncology · 2026Article
- Comprehensive pan-cancer analysis of MEX3C in human tumors.Discover oncology · 2026Article
- Proteomic stratification reveals immune metabolic heterogeneity in lung adenocarcinoma.Discover oncology · 2026Article
- Circ-MAP4K3 promotes papillary thyroid cancer progression by sponging miR-758-3p to enhance RRM2 expression.Clinical and experimental medicine · 2026Article
- Integrative multi-omics analysis identifies a circadian rhythm-associated gene signature for prognosis and therapeutic stratification in lung adenocarcinoma.Discover oncology · 2026Article
- RAS pathway activity subtypes identified by machine learning define prognostic and immune microenvironment characteristics in lung adenocarcinoma.Discover oncology · 2026Article
- Identification of replication factor C subunit 4 as a potential therapeutic target in esophageal squamous cell carcinoma based on bioinformatic analysis and machine learning.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: A highly aggressive and lethal malignancy, characterized by its heterogeneity, lung adenocarcinoma (LUAD) presents significant challenges in prognosis and treatment. Disulfidptosis, a newly identified form of regulated cell death, offers novel insights into cancer progression, yet its role in LUAD remains poorly understood. Methods: We identified disulfidptosis-related genes (DRGs) from prior studies and analyzed their interactions and functional enrichment. Molecular subtypes were identified through consensus clustering based on DRG expression, and a prognostic DRG signature was developed using multivariate Cox regression analysis. A nomogram integrating clinical variables was developed to predict survival. Comprehensive analyses, including single-cell RNA sequencing, immune infiltration, and drug sensitivity, were validated using clinical specimens, LUAD cell lines, Western blotting (WB) and immunohistochemistry (IHC). Results: A total of 16 DRGs were identified, classifying LUAD patients into three distinct subtypes with differential survival and immune profiles. A 4-gene signature ( Conclusions: This research highlights the essential role of DRGs in modulating the tumor microenvironment, influencing therapeutic response, and determining the prognosis of LUAD. The risk model and nomogram, derived from DRG expression, offer robust tools for survival prediction and personalized treatment stratification, facilitating the development of disulfidptosis-targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.